You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

Scratching the Surface: Understanding Itch in Prurigo Nodularis

Join experts Drs. Raja Sivamani and Sarina Elmariah as they discuss the clinical signs and high patient burden of PN, explore PN pathophysiology, and examine diagnostic challenges.

Raja Sivamani
Sarina Elmariah
MD, MS
Raja Sivamani +1 more

Learning objectives

  • Discuss itch as a burdensome symptom of many dermatology conditions
  • Understand how itch and clinical signs of prurigo nodularis are impacted by type 2 inflammation
  • Describe diagnostic challenges and considerations for prurigo nodularis
Tags
symposiumtype 2 inflammationquality of lifediagnosis
MAT-US-2412271 v1.0 - P Exp Date: 10/21/2026

About these experts

Dermatology
MD, MS

Raja Sivamani

Dr. Raja Sivamani is a board-certified dermatologist and practices as an integrative dermatologist at Pacific Skin Institute and an Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, and Director of Clinical Research and the Clinical Trials Unit.

Dermatology
MD, PhD

Sarina Elmariah

Associate Professor and Dermatology Director at the UCSF Centre for Itch and Neurosensory Disorders at the University of California in San Francisco, California, US

Related resources

Barrier Disruption in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Barrier Disruption in Atopic Dermatitis and Food Allergy

Type 2 Inflammation in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Type 2 Inflammation in Atopic Dermatitis and Food Allergy

Assessment of Atopic Dermatitis Burden in Children and Adolescents
Dermatology
expert video

Assessment of Atopic Dermatitis Burden in Children and Adolescents

Clinical Assessment of Prurigo Nodularis
Dermatology
expert video

Clinical Assessment of Prurigo Nodularis

Comorbidities in Children and Adolescents with Atopic Dermatitis
Dermatology
expert video

Comorbidities in Children and Adolescents with Atopic Dermatitis

A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU
Dermatology
expert video

A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU

An Overview of Prurigo Nodularis
Dermatology
expert video

An Overview of Prurigo Nodularis

Atopic Dermatitis as a Risk Factor for Food Allergy
Type 2 Inflammation
expert video

Atopic Dermatitis as a Risk Factor for Food Allergy

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation
Dermatology
expert video

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation

The Journey to Diagnosis: Considerations For AD, PN, and CSU
Dermatology
expert video

The Journey to Diagnosis: Considerations For AD, PN, and CSU

Pathophysiology of Prurigo Nodularis
Dermatology
expert video

Pathophysiology of Prurigo Nodularis

What is the disease burden of atopic dermatitis on children and their families
Dermatology
expert video

What is the disease burden of atopic dermatitis on children and their families

The Burden of Disease in Atopic Dermatitis
Dermatology
expert video

The Burden of Disease in Atopic Dermatitis

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice
Dermatology
expert video

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice

The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis
Dermatology
expert video

The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis

Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis
Dermatology
expert video

Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis
Dermatology
videoanimation

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.
Dermatology
Infographic

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

The Role of Mast Cells, Basophils, and Type 2 Cells and Cytokines in CSU
Dermatology
Infographic

The Role of Mast Cells, Basophils, and Type 2 Cells and Cytokines in CSU

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology
Dermatology
expert video

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Disease Modification Concepts in AD
Dermatology
expert video

Disease Modification Concepts in AD

Barrier disruption in AD and the development of environmental and food allergies
Dermatology
expert video

Barrier disruption in AD and the development of environmental and food allergies

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

CSU is Associated With a High Burden and Impact on Quality of Life
Dermatology
expert video

CSU is Associated With a High Burden and Impact on Quality of Life

How type 2 cytokines can amplify inflammatory response in CSU
Dermatology
expert video

How type 2 cytokines can amplify inflammatory response in CSU

Type 2 Inflammation and Infections
Type 2 Inflammation
slide presentation

Type 2 Inflammation and Infections

Skin Dyspigmentation In Prurigo Nodularis (PN)
Dermatology
interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region